MX2023002446A - Metodos y sistemas de prediccion de la respuesta a las terapias anti-tnf. - Google Patents
Metodos y sistemas de prediccion de la respuesta a las terapias anti-tnf.Info
- Publication number
- MX2023002446A MX2023002446A MX2023002446A MX2023002446A MX2023002446A MX 2023002446 A MX2023002446 A MX 2023002446A MX 2023002446 A MX2023002446 A MX 2023002446A MX 2023002446 A MX2023002446 A MX 2023002446A MX 2023002446 A MX2023002446 A MX 2023002446A
- Authority
- MX
- Mexico
- Prior art keywords
- systems
- methods
- predicting response
- tnf therapies
- tnf
- Prior art date
Links
- 238000002560 therapeutic procedure Methods 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 2
- 230000014509 gene expression Effects 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/70—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for mining of medical data, e.g. analysing previous cases of other patients
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
- G16H20/10—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
- G16B25/10—Gene or protein expression profiling; Expression-ratio estimation or normalisation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
- G16B40/20—Supervised data analysis
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B5/00—ICT specially adapted for modelling or simulations in systems biology, e.g. gene-regulatory networks, protein interaction networks or metabolic networks
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Physics & Mathematics (AREA)
- Medical Informatics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Data Mining & Analysis (AREA)
- Bioinformatics & Computational Biology (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Theoretical Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Evolutionary Biology (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Databases & Information Systems (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Primary Health Care (AREA)
- Bioethics (AREA)
- Computer Vision & Pattern Recognition (AREA)
- Evolutionary Computation (AREA)
- Software Systems (AREA)
- Artificial Intelligence (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Physiology (AREA)
- Mycology (AREA)
- Endocrinology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063073336P | 2020-09-01 | 2020-09-01 | |
| PCT/US2021/048346 WO2022051245A2 (en) | 2020-09-01 | 2021-08-31 | Methods and systems for predicting response to anti-tnf therapies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023002446A true MX2023002446A (es) | 2023-05-12 |
Family
ID=80492102
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023002446A MX2023002446A (es) | 2020-09-01 | 2021-08-31 | Metodos y sistemas de prediccion de la respuesta a las terapias anti-tnf. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230282367A1 (https=) |
| EP (1) | EP4208256A4 (https=) |
| JP (1) | JP2023538963A (https=) |
| KR (1) | KR20240018404A (https=) |
| CN (1) | CN117615780A (https=) |
| AU (1) | AU2021336781A1 (https=) |
| CA (1) | CA3191195A1 (https=) |
| GB (1) | GB2616129A (https=) |
| IL (1) | IL300978A (https=) |
| MX (1) | MX2023002446A (https=) |
| WO (1) | WO2022051245A2 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7496324B2 (ja) | 2018-03-16 | 2024-06-06 | サイファー メディシン コーポレイション | 抗ｔｎｆ療法に対する応答性を予測するための方法及びシステム |
| GB2603294A (en) | 2019-06-27 | 2022-08-03 | Scipher Medicine Corp | Developing classifiers for stratifying patients |
| WO2023150731A2 (en) * | 2022-02-04 | 2023-08-10 | Scipher Medicine Corporation | Systems and methods for predicting response to anti-tnf therapies |
| CN120015309B (zh) * | 2025-01-14 | 2025-12-12 | 中国人民解放军军事科学院军事医学研究院 | 用于急性高原反应（ams）易感性分群的装置 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008150491A2 (en) * | 2007-05-31 | 2008-12-11 | Abbott Laboratories | BIOMARKERS PREDICTIVE OF THE RESPONSIVENESS TO TNFα INHIBITORS IN AUTOIMMUNE DISORDERS |
| US20100303813A1 (en) * | 2007-06-08 | 2010-12-02 | Biogen Idec Ma Inc. | Biomarkers for predicting anti-tnf responsiveness or non-responsiveness |
| ES2445892T3 (es) * | 2008-08-25 | 2014-03-05 | Janssen Biotech, Inc. | Biomarcadores para el tratamiento anti-TNF en colitis ulcerosa y trastornos relacionados |
| WO2015148809A1 (en) * | 2014-03-27 | 2015-10-01 | Genentech, Inc. | Methods for diagnosing and treating inflammatory bowel disease |
| US12105089B2 (en) * | 2017-07-17 | 2024-10-01 | The Broad Institute, Inc. | Cell atlas of the healthy and ulcerative colitis human colon |
| JP7496324B2 (ja) * | 2018-03-16 | 2024-06-06 | サイファー メディシン コーポレイション | 抗ｔｎｆ療法に対する応答性を予測するための方法及びシステム |
| EA202191354A1 (ru) * | 2018-11-15 | 2021-08-11 | Янссен Байотек, Инк. | Способы и композиции для прогнозирования ответа на терапию воспалительного заболевания кишечника |
| GB2603294A (en) * | 2019-06-27 | 2022-08-03 | Scipher Medicine Corp | Developing classifiers for stratifying patients |
-
2021
- 2021-08-31 KR KR1020237011014A patent/KR20240018404A/ko active Pending
- 2021-08-31 CA CA3191195A patent/CA3191195A1/en active Pending
- 2021-08-31 MX MX2023002446A patent/MX2023002446A/es unknown
- 2021-08-31 WO PCT/US2021/048346 patent/WO2022051245A2/en not_active Ceased
- 2021-08-31 CN CN202180074291.7A patent/CN117615780A/zh active Pending
- 2021-08-31 AU AU2021336781A patent/AU2021336781A1/en not_active Abandoned
- 2021-08-31 GB GB2303624.7A patent/GB2616129A/en active Pending
- 2021-08-31 IL IL300978A patent/IL300978A/en unknown
- 2021-08-31 EP EP21864967.1A patent/EP4208256A4/en not_active Withdrawn
- 2021-08-31 JP JP2023513939A patent/JP2023538963A/ja active Pending
-
2023
- 2023-02-28 US US18/176,288 patent/US20230282367A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR20240018404A (ko) | 2024-02-13 |
| WO2022051245A2 (en) | 2022-03-10 |
| EP4208256A2 (en) | 2023-07-12 |
| US20230282367A1 (en) | 2023-09-07 |
| JP2023538963A (ja) | 2023-09-12 |
| CN117615780A (zh) | 2024-02-27 |
| EP4208256A4 (en) | 2024-09-25 |
| GB202303624D0 (en) | 2023-04-26 |
| GB2616129A (en) | 2023-08-30 |
| WO2022051245A3 (en) | 2022-04-14 |
| CA3191195A1 (en) | 2022-03-10 |
| IL300978A (en) | 2023-04-01 |
| AU2021336781A1 (en) | 2023-05-11 |
| AU2021336781A9 (en) | 2025-03-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2023002446A (es) | Metodos y sistemas de prediccion de la respuesta a las terapias anti-tnf. | |
| MX2021007810A (es) | Sistemas y métodos para el manejo de fuente de gas inteligente y/o sistemas y métodos para suministro de gas terapéutico y/o verificación de desempeño mejorada para suministro de gas terapéutico. | |
| WO2018231762A8 (en) | Systems and methods for identifying cancer treatments from normalized biomarker scores | |
| Yang et al. | A comprehensive analysis of immune infiltration in the tumor microenvironment of osteosarcoma | |
| Verstockt et al. | Intestinal receptor of SARS-CoV-2 in inflamed IBD tissue seems downregulated by HNF4A in ileum and upregulated by interferon regulating factors in colon | |
| Lumry et al. | Quality of life in patients with hereditary angioedema receiving therapy for routine prevention of attacks | |
| Cossburn et al. | Clinical relevance of differential lymphocyte recovery after alemtuzumab therapy for multiple sclerosis | |
| WO2019232542A3 (en) | Methods and compositions for detecting and modulating microenvironment gene signatures from the csf of metastasis patients | |
| Harrison et al. | Predictors for influenza vaccine acceptance among patients with inflammatory rheumatic diseases | |
| MX2022000128A (es) | Desarrollo de clasificadores para estratificar pacientes. | |
| EP4546365A3 (en) | Wearable automated medication delivery system | |
| WO2023150731A8 (en) | Systems and methods for predicting response to anti-tnf therapies | |
| Kochenderfer et al. | Anti-CD19 CAR T cells administered after low-dose chemotherapy can induce remissions of chemotherapy-refractory diffuse large B-cell lymphoma | |
| Yang et al. | Regulation of cancer immune escape: The roles of miRNAs in immune checkpoint proteins | |
| Morandi et al. | IL‐10 and ARG‐1 concentrations in bone marrow and peripheral blood of metastatic neuroblastoma patients do not associate with clinical outcome | |
| MX2014000204A (es) | Metodo de administracion y tratamiento. | |
| Korten et al. | Outcomes of initial antiretroviral treatment (ART) among recently diagnosed HIV patients in HIV‐TR cohort, 2011–2012 | |
| CA2993735C (en) | In-vitro methods for the detection of autoimmune diseases or conditions | |
| Hao et al. | Interaction between group 3 innate lymphoid cells, microbiota, and intestinal diseases: mechanisms and therapeutic potential | |
| MX2019007012A (es) | Marcadores geneticos humanos asociados con la respuesta a tratamientos que se dirigen a la toxina b de clostridium difficile. | |
| Xie et al. | OP0126 IS IMMUNE CHECKPOINT INHIBITORS THERAPIES SAFE AND EFFECTIVE FOR PATIENTS WITH CANCER AND PREEXISTING AUTOIMMUNE DISEASE? | |
| WO2018208783A3 (en) | Roving reference diagnostic system | |
| Santos-Moreno et al. | FRI0181 Effectiveness of biological therapy using a treat to target strategy in patients with rheumatoid arthritis | |
| Soto et al. | EE245 Budget Impact of Inotersen for the Treatment of Stage I or II Polyneuropathy in Adult Patients With Hereditary Transthyretin Amyloidosis (hATTR) in Public Health Mexico | |
| Onishi et al. | EE246 Consideration of the Cost of Adverse Events for Oncology Treatment: A Review of Cost-Effectiveness Evaluations in Japan |